Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Aes-103

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

5-hydroxymethylfurfural

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
  • M. Safo, G. Kato
  • Hematology/oncology clinics of North America
  • 2014
  • Corpus ID: 9014903
The pathophysiology of sickle cell disease involves the polymerization of sickle hemoglobin in its T state, which develops under… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2014
Highly Cited
2014
Imaging flow cytometry for automated detection of hypoxia‐induced erythrocyte shape change in sickle cell disease
In preclinical and early phase pharmacologic trials in sickle cell disease, the percentage of sickled erythrocytes after… 
2014
2014
Quantification of Anti-Sickling Effect of Aes-103 in Sickle Cell Disease Using an in Vitro Microfluidic Assay
Background: Under hypoxic conditions, sickle hemoglobin (HbS) polymerizes, causing morphologic distortion (sickling) of red blood… 
Review
2013
Review
2013
Phase 1 Clinical Trial Of The Candidate Anti-Sickling Agent Aes-103 In Adults With Sickle Cell Anemia
Abstract Background Aes-103 (5-hydroxymethylfurfural, 5-HMF) is a putative anti-sickling agent that has undergone pre-clinical… 
2012
2012
A Phase 1, First-in-Man, Dose-Response Study of Aes-103 (5-HMF), an Anti-Sickling, Allosteric Modifier of Hemoglobin Oxygen Affinity in Healthy Norman Volunteers
Abstract 3210 5-HMF (5-hydroxymethyl-2-furfural; Aes-103) is a breakdown product of glucose that has potent anti-sickling… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE